AcquisitionsMay 12, 2026, 04:07 PM
Stereotaxis Acquires Robocath; Q1 Revenue $6.3M
AI Summary
Stereotaxis reported Q1 2026 financial results and significant business updates, including a definitive agreement to acquire Robocath to create a leading robotic platform. The company also announced U.S. FDA approvals for its proprietary MAGiC catheter and Synchrony digital operating room system, which are now being utilized. While Q1 revenue decreased to $6.3 million from $7.5 million year-over-year and net loss slightly widened to $(5.9) million, Stereotaxis anticipates double-digit revenue growth for the full year 2026, expecting to surpass $40 million, driven by new product adoption and manufacturing ramp-up.
Key Highlights
- Definitive agreement to acquire Robocath, creating a leading robotic platform.
- Proprietary MAGiC catheter received U.S. FDA approval in January and is now in use.
- Synchrony digital operating room system received U.S. FDA clearance in April.
- Q1 2026 total revenue was $6.3 million, down from $7.5 million in Q1 2025.
- Q1 2026 net loss was $(5.9) million, compared to $(5.8) million in Q1 2025.
- Gross margin for Q1 2026 was 60% of revenue.
- Cash and cash equivalents stood at $14.6 million with no debt as of March 31, 2026.
- Anticipates double-digit revenue growth for full year 2026, surpassing $40 million.